Dec 19, 2022 Press Releases
PDF Version SAN FRANCISCO – December 19, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced today that the European Commission (EC) and European...
Oct 17, 2022 Press Releases
PDF Version SAN FRANCISCO, Calif. – October 17, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that the first subject has been dosed in...
Sep 8, 2022 Press Releases
PDF Version AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosis in multiple organs Sensitivity in those with previously diagnosed cardiac disease was 100% in ATTR and 93% in AL Organ-specific changes in...
Sep 7, 2022 Press Releases
PDF Version AT-04 demonstrates potent binding and promotes phagocytosis in ATTR and AL amyloidosis AT-04 binds potently to Aβ, tau, and α-synuclein, common amyloid pathologies in CNS disorders such as Alzheimer’s SAN FRANCISCO, Calif. – September 7, 2022 –...
Sep 6, 2022 Press Releases
PDF Version Human CAR-M cells can be generated with the pan-amyloid reactive p5 peptide as the target amyloid recognition element This novel system may serve as an adjunct to anti-amyloid monoclonal antibodies for the enhanced clearance of tissue amyloid SAN...
